

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1344737/publications.pdf Version: 2024-02-01



IÃ:N ROSA

#	Article	IF	CITATIONS
1	Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. European Heart Journal, 2014, 35, 3122-3133.	1.0	249
2	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. Hypertension, 2015, 65, 407-413.	1.3	178
3	Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension, 2017, 69, 1113-1120.	1.3	150
4	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. Journal of Hypertension, 2013, 31, 2455-2461.	0.3	136
5	Adrenalectomy Improves Arterial Stiffness in Primary Aldosteronism. American Journal of Hypertension, 2008, 21, 1086-1092.	1.0	89
6	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. Hypertension, 2016, 67, 397-403.	1.3	73
7	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	0.7	65
8	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	1.3	61
9	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. Journal of Human Hypertension, 2010, 24, 625-630.	1.0	57
10	Changes in Energy Metabolism in Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1651-1658.	1.8	49
11	Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertension Research, 2011, 34, 296-300.	1.5	42
12	Hyperresponders vs. nonresponder patients after renal denervation. Journal of Hypertension, 2014, 32, 2422-2427.	0.3	37
13	Long-term effect of specific treatment of primary aldosteronism on carotid intima–media thickness. Journal of Hypertension, 2015, 33, 874-882.	0.3	35
14	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertension Research, 2010, 33, 454-459.	1.5	34
15	Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. Kidney and Blood Pressure Research, 2012, 35, 529-533.	0.9	30
16	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1109-1117.	1.0	29
17	Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5170-5180.	1.8	28
18	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. Journal of Hypertension, 2017, 35, 1093-1099.	0.3	25

JÃin Rosa

#	Article	IF	CITATIONS
19	Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?. Journal of Human Hypertension, 2014, 28, 684-688.	1.0	23
20	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. Journal of Hypertension, 2018, 36, 221-229.	0.3	20
21	Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. Journal of Human Hypertension, 2016, 30, 35-39.	1.0	19
22	Primary Aldosteronism and Pregnancy. Kidney and Blood Pressure Research, 2020, 45, 275-285.	0.9	16
23	Discrepant Results of Adrenal Venous Sampling in Seven Patients with Primary Aldosteronism. Kidney and Blood Pressure Research, 2012, 35, 205-210.	0.9	14
24	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2422.	1.8	14
25	Catecholamines Induce Left Ventricular Subclinical Systolic Dysfunction: A Speckle-Tracking Echocardiography Study. Cancers, 2019, 11, 318.	1.7	13
26	Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. Cor Et Vasa, 2014, 56, e235-e239.	0.1	9
27	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 426-434.	1.0	8
28	The determinants of blood pressure response to exercise. Cor Et Vasa, 2015, 57, e163-e167.	0.1	6
29	Should All Patients with Resistant Hypertension Receive Spironolactone?. Current Hypertension Reports, 2016, 18, 81.	1.5	6
30	Technical and safety aspects of renal denervation. Cor Et Vasa, 2014, 56, e228-e234.	0.1	5
31	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. Cancers, 2019, 11, 485.	1.7	2
32	Biochemical Testing After Pheochromocytoma Removal: How Early?. Hormone and Metabolic Research, 2015, 47, 633-636.	0.7	1
33	(Prediction of long-term renal denervation efficacy). Cor Et Vasa, 2019, 61, e378-e384.	0.1	0
34	The revival of catheter-based renal denervation?. Intervencni A Akutni Kardiologie, 2018, 17, 159-163.	0.0	0